KR20140101730A - 글라티라머 아세테이트에 대한 임상 반응을 예측하는 데 유용한 단일 뉴클레오티드 다형성 - Google Patents

글라티라머 아세테이트에 대한 임상 반응을 예측하는 데 유용한 단일 뉴클레오티드 다형성 Download PDF

Info

Publication number
KR20140101730A
KR20140101730A KR1020147012550A KR20147012550A KR20140101730A KR 20140101730 A KR20140101730 A KR 20140101730A KR 1020147012550 A KR1020147012550 A KR 1020147012550A KR 20147012550 A KR20147012550 A KR 20147012550A KR 20140101730 A KR20140101730 A KR 20140101730A
Authority
KR
South Korea
Prior art keywords
snps
rti
kit
snp
glatiramer acetate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020147012550A
Other languages
English (en)
Korean (ko)
Inventor
아미르 체렛
파비오 맥차르디
조셉 레비
Original Assignee
테바 파마슈티컬 인더스트리즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 테바 파마슈티컬 인더스트리즈 리미티드 filed Critical 테바 파마슈티컬 인더스트리즈 리미티드
Publication of KR20140101730A publication Critical patent/KR20140101730A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020147012550A 2011-10-10 2012-10-09 글라티라머 아세테이트에 대한 임상 반응을 예측하는 데 유용한 단일 뉴클레오티드 다형성 Withdrawn KR20140101730A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161545282P 2011-10-10 2011-10-10
US61/545,282 2011-10-10
US201261636560P 2012-04-20 2012-04-20
US61/636,560 2012-04-20
PCT/US2012/059352 WO2013055683A1 (en) 2011-10-10 2012-10-09 Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate

Publications (1)

Publication Number Publication Date
KR20140101730A true KR20140101730A (ko) 2014-08-20

Family

ID=48082342

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147012550A Withdrawn KR20140101730A (ko) 2011-10-10 2012-10-09 글라티라머 아세테이트에 대한 임상 반응을 예측하는 데 유용한 단일 뉴클레오티드 다형성

Country Status (17)

Country Link
US (2) US8815511B2 (https=)
EP (1) EP2765857A4 (https=)
JP (1) JP2014530819A (https=)
KR (1) KR20140101730A (https=)
CN (1) CN103957705A (https=)
AR (1) AR088294A1 (https=)
AU (1) AU2012323345A1 (https=)
BR (1) BR112014008752A2 (https=)
CA (1) CA2851510A1 (https=)
EA (1) EA201490749A1 (https=)
HK (1) HK1200274A1 (https=)
IL (1) IL231723A0 (https=)
MX (1) MX2014004309A (https=)
TW (1) TW201326399A (https=)
UY (1) UY34380A (https=)
WO (1) WO2013055683A1 (https=)
ZA (1) ZA201403049B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ598661A (en) 2009-08-20 2013-02-22 Yeda Res & Dev Low frequency glatiramer acetate therapy
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
CA2814500A1 (en) 2010-10-11 2012-04-19 Teva Pharmaceutical Industries Ltd Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
HK1200274A1 (en) 2011-10-10 2015-08-07 Teva Pharmaceutical Industries Ltd. Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
HK1213830A1 (zh) * 2012-10-10 2016-07-15 Teva Pharmaceutical Industries Ltd. 用於预测醋酸格拉替雷临床反应的生物标志物
UY35790A (es) * 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
JP6432974B2 (ja) * 2014-06-20 2018-12-05 国立大学法人東北大学 ＴａｇＳＮＰの選択方法、選択用コンピュータシステム、及び、選択用ソフトウエア
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
WO2016172124A1 (en) * 2015-04-21 2016-10-27 Teva Pharmaceutical Industries Ltd. Select single nucleotide polymorphisms predictive of response to glatiramer acetate
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
CN109982712A (zh) 2016-08-31 2019-07-05 Mapi医药公司 包含醋酸格拉替雷的储库系统
CN110382052A (zh) 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
US11396825B2 (en) * 2017-08-14 2022-07-26 General Electric Company Turbine diagnostic feature selection system
WO2020092753A1 (en) * 2018-11-01 2020-05-07 I2Dx, Inc. Intelligent system and methods for therapeutic target identification
EP3976829A4 (en) * 2019-05-30 2023-07-12 PolygenRx Pty Ltd METHODS OF TREATMENT OR PROPHYLAXIS

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
IL113812A (en) 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US6214791B1 (en) 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
IL119989A0 (en) 1997-01-10 1997-04-15 Yeda Res & Dev Pharmaceutical compositions for oral treatment of multiple sclerosis
ES2527760T3 (es) 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
IL141021A0 (en) 1998-07-23 2002-02-10 Yeda Res & Dev Treatment of autoimmune conditions with copolymer 1 and related copolymers
WO2000005249A2 (en) 1998-07-23 2000-02-03 The President And Fellows Of Harvard College Synthetic peptides and methods of use for autoimmune disease therapies
US6514938B1 (en) 1998-09-25 2003-02-04 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
DK2239269T3 (da) 1998-09-25 2013-04-29 Yeda Res & Dev Anvendelse af peptider afledt af copolymer-1 som molekylvægtsmarkører
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
WO2000020010A1 (en) 1998-10-02 2000-04-13 Yeda Research And Development Co., Ltd. Alternate day administration of copolymer 1 for treating autoimmune diseases
AU775073C (en) 1998-11-12 2007-05-03 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating GVHD and HVGD
JP4328050B2 (ja) 2000-01-20 2009-09-09 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 神経保護療法のためのコポリマー１、関連ペプチド及びポリペプチドならびにそれらによって処理されたｔ細胞の使用
IL150895A0 (en) 2000-02-18 2003-02-12 Teva Pharma Oral, nasal and pulmonary formulations of copolymer-1
US7022663B2 (en) 2000-02-18 2006-04-04 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
HUP0302333A3 (en) 2000-06-05 2005-07-28 Teva Pharma The use of glatiramer acetate (copolymer 1) for the preparation of pharmaceutical compositions available in the treatment of central nervous system disorders
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
EP1294390B1 (en) 2000-06-07 2006-01-04 YEDA RESEARCH AND DEVELOPMENT CO., Ltd. The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotection from glutamate toxicity
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
US7429374B2 (en) 2001-12-04 2008-09-30 Teva Pharmaceutical Industries, Ltd. Process for the measurement of the potency of glatiramer acetate
US7351686B2 (en) 2001-12-06 2008-04-01 Yeda Research And Development Co. Ltd. Method for neuronal protection in amyotrophic lateral sclerosis by a vaccine comprising Copolymer-1 or Copolymer-1 related peptides
US7507531B2 (en) 2002-10-17 2009-03-24 Decode Genetics Chf. Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction
US7851486B2 (en) 2002-10-17 2010-12-14 Decode Genetics Ehf. Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
US20080293750A1 (en) 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
US20060019269A1 (en) 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
WO2004043995A2 (en) 2002-11-13 2004-05-27 Apotex Pharmachem Inc. Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine
ES2386435T3 (es) 2003-01-07 2012-08-21 Yeda Research And Development Co., Ltd. Vacuna en forma de gotas oculares que contiene copolímero 1 para inmunización terapéutica
RU2339397C2 (ru) 2003-01-21 2008-11-27 Йеда Рисерч Энд Дивелопмент Ко.Лтд. Сор1 для лечения воспалительных заболеваний кишечника
US20070037740A1 (en) 2003-03-04 2007-02-15 Irit Pinchasi Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
WO2004103297A2 (en) 2003-05-14 2004-12-02 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis
US20050064483A1 (en) * 2003-08-28 2005-03-24 Baylor College Of Medicine Gene expression profiling technology for treatment evaluation of multiple sclerosis
WO2005030955A1 (ja) 2003-09-29 2005-04-07 Chugai Seiyaku Kabushiki Kaisha Nk細胞に発現するタンパク質
JP2007509981A (ja) 2003-10-31 2007-04-19 テバ ファーマシューティカル インダストリーズ リミティド 薬物デリバリー用ナノ粒子
JP5456235B2 (ja) 2003-11-12 2014-03-26 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 神経変性疾患を治療するためのワクチン及び方法
US20100216863A1 (en) 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
JP2007538003A (ja) 2004-01-30 2007-12-27 デコード ジェネティクス イーエッチエフ． 心筋梗塞、脳卒中および末梢動脈閉塞疾患に対する感受性遺伝子、治療の方法
US20050266432A1 (en) * 2004-02-26 2005-12-01 Illumina, Inc. Haplotype markers for diagnosing susceptibility to immunological conditions
EP1778286A4 (en) 2004-03-03 2009-04-08 Teva Pharma COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE
US20050266410A1 (en) 2004-05-19 2005-12-01 Emily Walsh Methods of Human Leukocyte Antigen typing by neighboring single nucleotide polymorphism haplotypes
CN101039691B (zh) * 2004-06-25 2013-07-31 魁北克益得生物医学公司 用于治疗神经疾病的组合物和方法
EP1796710A4 (en) 2004-09-02 2010-05-26 Teva Pharma THERAPY COMBINED WITH GLATIRAMER ACETATE AND N-ACETYLCYSTEINE TO TREAT MULTIPLE SCLEROSIS
ZA200702591B (en) 2004-09-09 2009-03-25 Teva Pharma Process for preparation of mixtures of polypeptides using purified hydrobromic acid
HRP20160455T1 (hr) 2004-09-09 2016-07-15 Yeda Research And Development Co., Ltd. Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene
AR052321A1 (es) 2004-10-29 2007-03-14 Sandoz Ag Procesos para la preparacion de un polipeptido
JP2008528589A (ja) 2005-02-02 2008-07-31 テバ ファーマシューティカル インダストリーズ リミティド 水素化分解を用いてポリペプチド混合物を作成する方法
US20100167983A1 (en) 2007-10-22 2010-07-01 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
WO2006089164A1 (en) 2005-02-17 2006-08-24 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
CA2606194A1 (en) 2005-04-25 2006-11-02 Yeda Research And Development Company Markers associated with the therapeutic efficacy of glatiramer acetate
US20070059798A1 (en) 2005-09-09 2007-03-15 Alexander Gad Polypeptides useful for molecular weight determinations
WO2007081975A2 (en) 2006-01-11 2007-07-19 Teva Pharmaceutical Industries, Ltd. Method of treating multiple sclerosis
US20080118553A1 (en) 2006-06-12 2008-05-22 Anton Frenkel Tannate salt form of polypeptide mixtures, their preparation and use
JP2009542864A (ja) 2006-07-05 2009-12-03 モメンタ ファーマシューティカルズ インコーポレイテッド コポリマー１の調製のための改良法
US20080131887A1 (en) * 2006-11-30 2008-06-05 Stephan Dietrich A Genetic Analysis Systems and Methods
US7795033B2 (en) 2007-03-19 2010-09-14 The United States Of America As Represented By The Department Of Health And Human Services Methods to predict the outcome of treatment with antidepressant medication
CA2702437C (en) 2007-11-28 2013-06-25 Teva Pharmaceutical Industries Ltd. Method of delaying the onset of clinically definite multiple sclerosis
US20090177487A1 (en) 2008-01-07 2009-07-09 Tera Eerkes Methods for Assessing Genetic Compatibility
US20110158979A1 (en) 2008-06-13 2011-06-30 Prognomix, Inc. Genetic component of complications in type 2 diabetes
AU2009266947A1 (en) 2008-07-04 2010-01-07 Axial Biotech, Inc Genetic markers associated with degenerative disc disease and uses thereof
EP2406396A2 (en) * 2009-03-12 2012-01-18 Brainco Biopharma, S.L. A genotyping tool for improving the prognostic and clinical management of ms patients
US20120073585A1 (en) 2009-04-08 2012-03-29 Cedars-Sinai Medical Center Methods of predicting complication and surgery in crohn's disease
US8920373B2 (en) 2009-07-15 2014-12-30 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration
CA2697570C (en) 2009-07-15 2011-11-01 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration
NZ598661A (en) 2009-08-20 2013-02-22 Yeda Res & Dev Low frequency glatiramer acetate therapy
US8853378B2 (en) 2009-10-09 2014-10-07 Georgetown University Polynucleotides that home to atherosclerotic plaque
US8759302B2 (en) * 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
CA2814500A1 (en) 2010-10-11 2012-04-19 Teva Pharmaceutical Industries Ltd Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
HK1200274A1 (en) 2011-10-10 2015-08-07 Teva Pharmaceutical Industries Ltd. Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
HK1213830A1 (zh) 2012-10-10 2016-07-15 Teva Pharmaceutical Industries Ltd. 用於预测醋酸格拉替雷临床反应的生物标志物
AU2013361057A1 (en) 2012-12-21 2015-07-30 Teva Pharmaceutical Industries Ltd. Oral transmucosal delivery of glatiramer acetate
KR20150111918A (ko) 2012-12-21 2015-10-06 테바 파마슈티컬 인더스트리즈 리미티드 글라티라머 아세테이트의 경점막 전달
MX2015008754A (es) 2013-01-04 2016-04-11 Teva Pharma Caracterizacion de un medicamento relacionado con acetato de glatiramer.
US20140271630A1 (en) 2013-03-12 2014-09-18 Teva Pharmaceutical Industries, Ltd. Rituximab induction therapy followed by glatiramer acetate therapy
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product

Also Published As

Publication number Publication date
JP2014530819A (ja) 2014-11-20
US9499868B2 (en) 2016-11-22
CA2851510A1 (en) 2013-04-18
CN103957705A (zh) 2014-07-30
IL231723A0 (en) 2014-05-28
WO2013055683A1 (en) 2013-04-18
MX2014004309A (es) 2015-07-06
EA201490749A1 (ru) 2014-09-30
TW201326399A (zh) 2013-07-01
AU2012323345A1 (en) 2014-05-22
HK1200274A1 (en) 2015-08-07
US20150045306A1 (en) 2015-02-12
ZA201403049B (en) 2015-09-30
UY34380A (es) 2013-05-31
EP2765857A1 (en) 2014-08-20
EP2765857A4 (en) 2015-12-09
US20130123189A1 (en) 2013-05-16
AR088294A1 (es) 2014-05-21
NZ624258A (en) 2016-09-30
BR112014008752A2 (pt) 2017-04-25
US8815511B2 (en) 2014-08-26

Similar Documents

Publication Publication Date Title
KR20140101730A (ko) 글라티라머 아세테이트에 대한 임상 반응을 예측하는 데 유용한 단일 뉴클레오티드 다형성
Kraft et al. Sequence analysis of the serotonin transporter and associations with antidepressant response
Johnson et al. Exome sequencing reveals riboflavin transporter mutations as a cause of motor neuron disease
US9702007B2 (en) Genetic markers predictive of response to glatiramer acetate
EP2841068B1 (en) Crhr1 antagonists for use in the treatment of patients having crh overactivity
US20150278438A1 (en) Genetic predictors of response to treatment with crhr1 antagonists
DK2411535T3 (en) BIOMAR RUNNING FOR ASSESSMENT OF PERIPHERAL NEUROPATHY RESPONSE TO TREATMENT WITH a proteasome inhibitor
EP3011048A1 (en) Method for predicting a treatment response to a crhr1 antagonist and/or a v1b antagonist in a patient with depressive and/or anxiety symptoms
Srour et al. DOK7 mutations presenting as a proximal myopathy in French Canadians
KR100964473B1 (ko) 단일염기다형성을 이용한 항우울제 치료효과에 관한 정보를제공하는 방법
US20160312284A1 (en) Select single nucleotide polymorphisms predictive of response to glatiramer acetate
JP5904501B2 (ja) ２型糖尿病の検出方法
Class et al. Patent application title: DETERMINATION OF SINGLE NUCLEOTIDE POLYMORPHISMS USEFUL TO PREDICT RESPONSE FOR GLATIRAMER ACETATE Inventors: Teva Pharmaceutical Industries, Ltd.(Petach-Tikva, IL) Amir Tchelet (Hod-Hasharon, IL) Fabio Macciardi (Irvine, CA, US) Joseph Levy (Kfar-Sava, IL) Assignees: Teva Pharmaceutical Industries Ltd.
US9309572B2 (en) Acid ceramidase polymorphisms and methods of predicting traits using the acid ceramidase polymorphisms
Motazacker et al. 603 COMBINING EXOME SEQUENCING WITH EXCLUSION LINKAGE ANALYSIS AS A TOOL TO UNRAVEL THE MOLECULAR BASIS OF A COMMON GENETIC DISEASE
Frever et al. 604 REGULATION AND FUNCTIONAL ANALYSIS OF MRAS
JP2022526427A (ja) 神経障害の治療への反応に関連する遺伝的変異体
Wang et al. A pharmacogenomic study on the polymorphic gene response to risperidone in schizophrenia patients
US20060008832A1 (en) Methods for identifying a candidate for treatment of obesity

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid
R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000